Introduction
Type I diabetes, also known as insulin-dependent diabetes mellitus (IDDM), is an autoimmune disorder where the insulin-producing ␤-cells of the pancreas in the islets of Langerhans are destroyed. Although a significant genetic component contributes to the susceptibility, an unidentified environmental factor is required to initiate the inflammation around and in the islets. 1, 2 It is known that cells capable of presenting antigen-like macrophages and dendritic cells do reside in the islets. 3, 4 The function of antigen-presenting cells such as macrophages and dendritic cells, therefore, would be a logical target for immunoregulation to inhibit antigen uptake, migration out of the islets and co-stimulation function in the peripheral lymphoid organs. Inhibition of antigen-presenting cells locally in islets would prevent the activation of autoreactive T cells. In addition, the migration of leukocyte effectors into the islets, as well as their function could also be blocked by molecules expressed at protective levels from within islets.
IL-1␤ has been shown to be important for the induction of nitric oxide in islets, resulting in islet dysfunction. 4, 5 Moreover, IL-1␤ is able to induce Fas expression on the surface of ␤-cells which can result in FasL-mediated apoptosis by T cells during the onset of insulitis. 6, 7 Treatment of NOD mice with interleukin 1 receptor antagonist protein following transplantation of syngeneic islets blocks autoimmune mediated rejection of the transplanted islets. 8 Thus the local inhibition of IL-1␤ by gene transfer of IL-1 inhibitors to islets could be used to block the onset of autoimmune-mediated islet dysfunction and apoptosis following transplantation. Islet transplantation is a viable therapy for type I diabetes, but the allogeneic response to donor antigen makes graft acceptance an important obstacle. Recently, the use of immunosuppressive cytokines like IL-10, TGF-␤ [9] [10] [11] and proteins that can block co-stimulation such as CTLA4Ig [12] [13] [14] [15] [16] and monoclonal antibodies against CD40L 17,18 has yielded promising results in a variety of animal models where allogeneic and even xenogeneic graft survival was significantly prolonged following engraftment. The local transfer of genes encoding immunosuppressive agents to islets could be used to prolong engraftment of allogeneic islets following transplantation.
A number of groups have successfully used virusmediated gene transfer of immunoregulatory genes such as IL-10, viral IL-10, CTLA4Ig to islets in vitro and in vivo, mostly employing E1-deleted, first-generation adenoviral vectors.
19-24 E1-deleted adenoviral vectors have been tested in human islets extensively and they do not appear to interfere with the function of the ␤-cell in vitro. 19, 20, 25 In vivo however, the inherent immunogenicity of these vehicles may actually be detrimental to the islet transplant, at least as it pertains to a gene therapy-based treatment of IDDM, where the virus and its proteins could induce a virus-specific immune response or even exacerbate an ongoing autoimmune attack. Furthermore, the non-integrating nature of adenoviral vectors will preclude long-term expression of therapeutically relevant genes. Nonetheless, many experiments addressing gene transfer to islets have been performed with adenoviral delivery vehicles with varying degrees of success.
Long-term, stable gene expression in islets requires a vector that can infect non-dividing cells, like ␤-cells which comprise about 60-80% of the islet cells, that can integrate into the cell genome and that is non-immunogenic. This is particularly important for in vivo gene delivery. Retroviruses, can stably integrate into the host genome but they cannot infect non-dividing cells, like teminally differentiated neurons, skeletal muscle and islet cells. 26 The recently engineered HIV-1 lentiviral vector possesses all three of these characteristics in vivo [27] [28] [29] and is therefore a logical candidate as a gene delivery vehicle to islets. In vivo, the lentiviral vector can stably infect nondividing neurons, retinal cells, liver and skeletal muscle of rats. [27] [28] [29] [30] In this report, we show that an HIV-1-based lentiviral vector can infect intact human islets in vitro with an efficiency similar to adenovirus. In addition, a lentiviral vector was used to deliver and express a therapeutic protein, interleukin-1 receptor antagonist (IL-1Ra) protein at a level similar to that from an adenoviral vector. Furthermore, we demonstrate that the function of the genetically modified islets is not impaired by viral infection in that they can respond normally to a glucose challenge. Taken together, our results demonstrate that lentiviral vectors could be used genetically to modify human islets for the purposes of transplantation as a therapeutic option for type I diabetes.
Results

Comparison of lentiviral and adenoviral gene transfer to human islets in vitro
In an initial attempt to evaluate the efficiency of infection by adenoviral and lentiviral vectors of intact human islets, equal plaque-forming units (pfu-adenovirus) or transducing-infectious units (TIU-lentivirus) of vectors carrying the ␤-galactosidase (LacZ) marker gene were used. Adenovirus (Ad)-LacZ infection was carried out for 4 h and overnight with lentivirus (LtV)-LacZ as described in Materials and methods. As shown in Figure 1 , both adenoviral and lentiviral vectors were able to infect the intact human islets with nearly identical efficiency (panels a and b are representative of the staining observed for all islets). The pattern and magnitude of ␤-galactosidase expression following adenoviral gene transfer to islets is in agreement with previously published data. 19, 20 There is no background ␤-galactosidase expression in uninfected human islets ( Figure 1 , panel c).
Since X-gal staining reveals only surface expression in intact islet and therefore could be misleading as to the true extent of gene transfer, single islet cells were analyzed by FACS following infection of intact islets with adenoviral and lentiviral vectors encoding the enhanced green fluorescent protein (eGFP). In Figure 2a we show representative single islet cell populations expressing eGFP (panel I: Ad-eGFP; panel II: LtV-eGFP). Although the fluorescence is generally higher in the Ad-eGFPinfected islet cells, the percentage of eGFP-positive cells is similar for Ad-eGFP and LtV-eGFP (approximately 70%). Islet cells obtained from uninfected islets do not fluoresce (panel III). Previous reports indicate that islet cells scatter between 1-15°forward scatter and that the predominant cell type in this peak is the ␤-cell. 31 Thus the cells were gated on meeting this scatter profile and concurrently evaluated for eGFP fluorescence. Analysis of the eGFPpositive cells indicated that the number of gated cells (ie ␤-cells) expressing enhanced green fluorescent protein was almost identical irrespective of whether lentivirus or adenovirus was used as the transfer vehicle ( Figure 2b , LtV-eGFP: 51.6 ± 0.8 versus Ad-eGFP: 47.8 ± 1.9; mean of three replicates ± s.e.m). These results demonstrate that both the adenovirus and lentivirus vectors are able to infect ␤-cells contained within intact islets efficiently. It is worth noting the variability of fluorescence intensity among cells in both the Ad-eGFP and LtV-eGFP experimental groups.
Interleukin 1␤ (IL-1␤) is able to stimulate NO production in islets in vitro, resulting in islet dysfunction. [32] [33] [34] The IL-1␤-dependent stimulation of NO also results in an increase in cell surface expression of Fas, as well as increasing islet apoptosis in vitro in response to Fas triggering. 6, 7 In addition, the inhibition of IL-1␤ by continuous systemic administration of IL-1Ra has been shown to block islet dysfunction, insulitis onset and diabetes in NOD mice. 8 Thus, as both a potentially therapeutic transgene and a secreted marker protein, stocks of lentiviral and adenoviral vectors expressing human interleukin-1 receptor antagonist protein were generated. Infection of 200 human islets with concentrated lentiviral IL-1Ra supernatant in triplicate in two separate experiments yielded 13.5 and 15.1 ng/ml IL-1Ra by ELISA in the medium 3 days later. Similarly, infection with Ad-IL-1Ra in triplicate in two separate experiments resulted in production of 29.4 and 32.6 ng/ml IL-1Ra, whereas mockinfected islets did not produce detectable IL-1Ra ( Figure 3 ).
Functional evaluation of ␤-cells in modified intact human islets
Previous data demonstrate that adenoviral infection of cultured islets in vitro does not impair ␤-cell function as assessed by glucose-stimulated insulin release into the culture supernatant. 25 The effect of lentiviral infection on ␤-cell function is currently not known. To determine if lentiviral infection and consequent transgene expression affects ␤-cell function, the modified islets were challenged with increasing concentrations of glucose in a glucose-free buffer. Figure 4 shows that insulin is secreted from virally infected islets (adenoviral and lentiviral) into a serum-free buffer in a glucose concentration-dependent manner over a half-hour challenge in vitro. The profile of the LtV-eGFP (1 × 10 6 TIU) response is identical to that of uninfected islets and islets infected with Ad-eGFP (1 × 
Discussion
It has been demonstrated previously that both murine and human islets are readily infected by adenoviral gene transfer vectors with very high efficiency. [19] [20] [21] Additionally, a series of immunoregulatory genes has been inserted into adenoviral vectors and expressed from murine islets transplanted into allogeneic and xenogeneic hosts. 11, [21] [22] [23] [24] Although long-term expression and protection of islets from rejection has been achieved under particular experimental conditions, 23 the non-integrating nature and inherent immunogenicity of the recombinant adenovirus necessitate the use of a stably integrating, non-immunogenic gene delivery system. In this report we have demonstrated that intact islets can be infected with a lentiviral vector to a degree similar to that of adenoviral vectors. Moreover, we demonstrate that the ␤-cells within the intact islet can be infected at an efficiency greater than 50%. The percentage of cells expressing a transgene following lentiviral infection of intact islets is in agreement with a recent report by Ju et al 35 examining infection of dispersed islet cells.
Although islets can be engineered to express molecules that can neutralize an immune response, a functional evaluation of the ␤-cell, the target of autoimmune attack in IDDM, is very important. Toxicity due to transgene product or to the viral proteins is always possible and in fact, murine islets infected with adenovirus at an MOI of 1000 have exhibited functional impairment in vitro most likely because of a high concentration of viral proteins. 25 A previous report indicates that, on average, there are 1000 cells per human islet 36 and based on this, many studies report infection on a multiplicity of infection (MOI) basis. However, the average cell number per human islet is highly variable and dependent on the state of donor pancreas, digestion procedure and isolation as well as viability in vitro. Therefore, for uniformity among experiments, we suggest using pfu or TIU as a unit of infectivity rather than MOI.
Although green fluorescent protein is a versatile tool for comparing the efficiency of different vectors to infect a given cell population or a tissue, there is variability of fluorescence among infected cells. The variability of the amount of green fluorescent protein expressed by individual cells within a population could be due to the level of transcription, the stability of the transcript among different cells and the choice of quantification method (FACS, quantitative one-dimensional fluorescence microscopy, confocal scanning laser microscopy, etc).
We show that lentiviral infection does not alter islet function as assessed by the insulin-secretory response of ␤-cells in a glucose concentration-dependent manner. Although we have not exhaustively evaluated islet cell integrity following adenoviral or lentiviral infection, for the viral concentrations used in these experiments, viability of single dispersed cells as assessed by trypan blue staining does not appear any different than cells from uninfected islets (75-80% viable, data not shown).
The ability to infect at least 50% of the ␤-cells with a lentiviral vector should allow for the transfer of genes encoding for protein which act intracellularly such as anti-apoptotic genes. However, for some applications like immunoprotection of transplanted islets as a therapy for type I diabetes, even a low transfer efficiency may be effective for conferring a protective or therapeutic effect when the transgene encodes a soluble protein. This may turn out to be the case for immunoregulatory cytokines whose genes are expressed at very high levels when under the control of a strong promoter like that of cytomegalovirus. 11, 21, 37 Indeed, even 5% of islet cells secreting a soluble protein such as IL-1Ra following lentiviral infection, may adequately suppress an autoimmune or allogeneic immune response.
There is strong evidence in support of IL-1␤, a proinflammatory cytokine expressed predominantly from macrophages, as the initial trigger of insulitis in response to an intra-islet lesion. 4, 5, 34, 38 IL-1␤ promotes nitric oxide formation and Fas expression in ␤-cells and blockade of IL-1␤ in vivo with continuous IL-Ra infusion prevented diabetes in a genetically susceptible animal model. [6] [7] [8] 39 The stably integrating nature of the lentiviral vector and the absence of immunogenicity in rat in vivo experiments compels us to pursue the lentiviral-IL-1Ra strategy in vivo. We are currently exploring a variety of biochemical manipulations to improve the efficiency of lentiviral gene transfer to human and mouse islets in vitro.
Materials and methods
Vector preparation An E1-deleted adenovirus encoding ␤-galactosidase (AdLacZ) or enhanced green fluorescent protein (Ad-eGFP) was designed and titered as described 40, 41 by cre-lox recombination with reagents generously provided by Somatix (Alameda, CA, USA). For the construction of the Ad-eGFP vector, a SnaBI-HpaI fragment containing part of the cytomegalovirus promoter, the enhanced green fluorescent protein (eGFP) cDNA and part of the SV40 poly(A) sequence (derived from pEGFP; Clontech, Palto Alto, CA, USA) was inserted into the pAdlox shuttle plasmid. El-substituted recombinant adenovirus was generated by co-transfection of SfiI-digested pAdlox-eGFP and 5 helper virus DNA into the adenoviral packaging cell line CRE8, propagated and purified as described. 40 Ad-IL-1Ra virus was obtained from Amgen (Boulder, CO, USA) and Ad-LacZ was generously provided by Genvec (Bethesda, MD, USA). Subsequent propagation was performed as described. 40, 41 The vesicular stomatitis virus G-protein (VSV-G)-pseudotyped lentiviral vectors encoding either ␤-galactosidase (LtV-LacZ), enhanced green fluorescent protein (LtV-eGFP) or the human IL-1Ra cDNA (LtV-1RAP) were generated using the three-plasmid system developed as described. 27, 28 Briefly, subconfluent 293T cells were cotransfected with the three plasmids and incubated for 2 a days in DMEM medium with 10% FCS, supplemented with 1% penicillin/streptomycin (Gibco-BRL, Gaithersburg, MD, USA) and containing l-glutamine. Following this incubation, the media were replaced with fresh media and after an overnight incubation, the media was collected, filtered through a 0.22 micron filter and ultracentrifuged at 107 100 g in an SW-41Ti rotor (Beckman, Fullerton, CA, USA) for 1 h 30 min at 4°C. The resulting viral pellet was dissolved in a minimal volume of Hank's balanced salt solution overnight and LtV-LacZ, LtV-eGFP were then titered as described on 293T cells. 28 Infection of human islets in vitro, visualization and detection of transgene expression and FACS analysis Human islets were obtained using the liberase enzyme blend. Pancreata were obtained from cadaveric donors and subjected to the digestion, isolation and purification as described. 42 We routinely obtained islets to a purity greater than 80% (mantled islets).
Figure 2 (a) eGFP expression in single dispersed islet cells derived from intact islets infected with Ad-eGFP or LtV-eGFP. Groups of 100-200 human islets were infected with Ad-eGFP of LtV-eGFP. eGFP-expressing islets were then dispersed and the single cells plated. Panel I illustrates islet cells obtained from islets infected with Ad-eGFP and panel II shows islet cells derived from islets infected with LtV-eGFP. Panel III shows that single cells derived from uninfected islets do not exhibit any fluorescence (×40 magnification). (b) FACS analysis of dispersed islet cells expressing
Groups of 200 islets were infected with Ad-LacZ or AdeGFP (1-2 × 10 6 pfu) for 4 h in a minimal volume of serum-free RPMI 1640 medium (Gibco-BRL) at 37°C. The islets were then washed extensively with serum-free RPMI 1640 and incubated for an additional 48 h in RPMI 1640 with 10% FCS. For LtV-LacZ or LtV-eGFP infection, an equal number of islets was cultured overnight in a minimal volume of concentrated viral supernatant adjusted to contain 1 × 10 6 TIU and 8 g/ml polybrene. The islets were then washed extensively with RPMI 1640 and the incubation was continued for an additional 48 h in RPMI 1640 with 10% fetal calf serum. For LtV-IL-1Ra, an equivalent number of islets were incubated in a minimal volume of medium containing 100 l of concentrated viral supernatant. At the end of the incubation, cultures were processed either for in situ ␤-galactosidase expression (Ad-LacZ and LtV-LacZ), dispersed into single cells for FACS analysis (Ad-eGFP and LtV-eGFP) or the media assayed for IL-1Ra (LtV-IL-1Ra) by ELISA. For ␤-galactosidase, the islets were washed twice with sterile PBS and then fixed in 0.5% glutaraldehyde/PBS for 30 min-1 h at 4°C. The glutaraldehyde was removed with three washes of PBS/1 mm MgCl 2 and stained with X-gal for 2-4 h at 37°C.
For FACS analysis, intact islets were dispersed into single cell suspensions as described. 36 The cell suspensions were subjected to FACS analysis in a Becton Dickinson FACStar Plus, with an argon laser set at 488 nm and with gated cells having a forward scatter between 1-15°. Under this selection, the majority of cells gated are ␤-cells as previously described. 31 IL-1Ra was detected by ELISA (R&D Systems, Minneapolis, MN, USA) 4 days later in the media as recommended by the manufacturer.
Functional evaluation of modified intact islets by glucose-stimulated insulin production To determine if viral infection affected ␤-cell function, the response of islets to a glucose challenge was tested by measuring insulin release into serum-free buffer. Islets (200 per well, in triplicate) infected with Ad-eGFP or LtVeGFP were washed extensively 3 days following infection, with Krebs-Ringer-HEPES buffer (KRH buffer; 25 mm HEPES pH 7.4, 115 mm NaCl, 24 mm NaHCO 3 , 5 mm KCl, 2.5 mm CaCl 2 and incubated for 30 min at 37°C. Immediately thereafter, glucose was added to a final concentration of 5, 12 and 18 mm and the incubation carried out for a further 30 min. The buffer was collected and insulin detected using a commercially available ELISA kit (CrystalChem, Chicago, IL, USA).
